HL-60/MX1
HL-60/MX1
规格:
货期:
编号:TS212000
品牌:Testobio
| 产品名称： | HL-60/MX1 |
|---|---|
| 商品货号： | TS212000 |
| Organism： | Homo sapiens, human |
| Product Format： | frozen |
| Morphology： | lymphoblast |
| Culture Properties： | suspension |
| Biosafety Level： | 1
Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country. |
| Disease： | acute promyelocytic leukemia |
| Age： | 36 years |
| Gender： | female |
| Ethnicity： | Caucasian |
| Applications： | HL-60/MX1 cells are cross resistant to etoposide, teniposide, bisantrene. |
| Derivation： | HL-60/MX1 is a mitoxantrone resistant derivative of the HL-60 cell line (see ATCC CCL-240) which was obtained from peripheral blood leukocytes obtained by leukopheresis from patient with acute promyelocytic leukemia. |
| Clinical Data： | HL-60/MX1 is a mitoxantrone resistant derivative of the HL-60 cell line (see ATCC CCL-240) which was obtained from peripheral blood leukocytes obtained by leukopheresis from patient with acute promyelocytic leukemia. female Caucasian 36 years |
| Comments： | HL-60/MX1 is a mitoxantrone resistant derivative of the HL-60 cell line (see ATCC CCL-240) which was obtained from peripheral blood leukocytes obtained by leukopheresis from patient with acute promyelocytic leukemia. The cells were selected and subcloned in 1987 for resistance to 39 nM mitoxantrone, an anthracenedione antitumor agent. Subsequent exposure of the HL-60/MX1 cells to higher concentrations of mitoxantrone led to the emergence of cells capable of growth at 190 nM (see ATCC CRL-2257, HL-60/MX2). HL-60/MX1 cells display atypical multidrug resistance (MDR), altered topoisomerase II catalytic activity and reduced levels of topoisomerase II alpha and beta proteins. HL-60/MX1 cells are cross resistant to etoposide, teniposide, bisantrene. Dactinomycin, 4-(9-acridinylamino)methane-sulfon-m-anisidide, and the anthracyclines daunorubicin and doxorubicin but retain sensitivity to the Vinca alkaloids vincristine and vinblastine, melphalan, mitomycin C and cisplatin. |
| Complete Growth Medium： | The base medium for this cell line is ATCC-formulated RPMI-1640 Medium, Catalog No. 30-2001. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 10%.
|
| Subculturing： | Medium Renewal: Every 2 to 3 days Cultures can be maintained by addition or replacement of medium. Start new cultures at 2 X 10 exp5 viable cells/ml and subculture at 1 X 10 exp6 cells/ml. |
| STR Profile： | Amelogenin: X CSF1PO: 13,14 D13S317: 8,11 D16S539: 11 D5S818: 12 D7S820: 11,12 THO1: 7,8 TPOX: 8 vWA: 16 |
| Name of Depositor： | WG Harker |
| Deposited As： | Homo sapiens |
| References： | Harker WG, et al. Multidrug resistance in mitoxantrone-selected HL-60 leukemia cells in the absence of P-glycoprotein overexpression. Cancer Res. 49: 4542-4549, 1989. PubMed: 2568172 |
首页 >
产品中心
>
微生物培养
>
菌株
>
null
>
HL-60/MX1
产品中心 Product Center
联系我们CONTACT US
-
0574-87917803
24小时服务热线 -
testobio@163.com
销售邮箱 -
浙江省宁波市高新区晶辉路866弄33号智造港E4幢3楼
地址
联系方式
-
章丽敏
17757489010 -
朱静
18067106081 -
李晴
18067408036 -
李晶晶
13375187189 -
周雪
13372109301
| 产品名称： | HL-60/MX1 |
|---|---|
| 商品货号： | TS212000 |
| Organism： | Homo sapiens, human |
| Product Format： | frozen |
| Morphology： | lymphoblast |
| Culture Properties： | suspension |
| Biosafety Level： | 1
Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country. |
| Disease： | acute promyelocytic leukemia |
| Age： | 36 years |
| Gender： | female |
| Ethnicity： | Caucasian |
| Applications： | HL-60/MX1 cells are cross resistant to etoposide, teniposide, bisantrene. |
| Derivation： | HL-60/MX1 is a mitoxantrone resistant derivative of the HL-60 cell line (see ATCC CCL-240) which was obtained from peripheral blood leukocytes obtained by leukopheresis from patient with acute promyelocytic leukemia. |
| Clinical Data： | HL-60/MX1 is a mitoxantrone resistant derivative of the HL-60 cell line (see ATCC CCL-240) which was obtained from peripheral blood leukocytes obtained by leukopheresis from patient with acute promyelocytic leukemia. female Caucasian 36 years |
| Comments： | HL-60/MX1 is a mitoxantrone resistant derivative of the HL-60 cell line (see ATCC CCL-240) which was obtained from peripheral blood leukocytes obtained by leukopheresis from patient with acute promyelocytic leukemia. The cells were selected and subcloned in 1987 for resistance to 39 nM mitoxantrone, an anthracenedione antitumor agent. Subsequent exposure of the HL-60/MX1 cells to higher concentrations of mitoxantrone led to the emergence of cells capable of growth at 190 nM (see ATCC CRL-2257, HL-60/MX2). HL-60/MX1 cells display atypical multidrug resistance (MDR), altered topoisomerase II catalytic activity and reduced levels of topoisomerase II alpha and beta proteins. HL-60/MX1 cells are cross resistant to etoposide, teniposide, bisantrene. Dactinomycin, 4-(9-acridinylamino)methane-sulfon-m-anisidide, and the anthracyclines daunorubicin and doxorubicin but retain sensitivity to the Vinca alkaloids vincristine and vinblastine, melphalan, mitomycin C and cisplatin. |
| Complete Growth Medium： | The base medium for this cell line is ATCC-formulated RPMI-1640 Medium, Catalog No. 30-2001. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 10%.
|
| Subculturing： | Medium Renewal: Every 2 to 3 days Cultures can be maintained by addition or replacement of medium. Start new cultures at 2 X 10 exp5 viable cells/ml and subculture at 1 X 10 exp6 cells/ml. |
| STR Profile： | Amelogenin: X CSF1PO: 13,14 D13S317: 8,11 D16S539: 11 D5S818: 12 D7S820: 11,12 THO1: 7,8 TPOX: 8 vWA: 16 |
| Name of Depositor： | WG Harker |
| Deposited As： | Homo sapiens |
| References： | Harker WG, et al. Multidrug resistance in mitoxantrone-selected HL-60 leukemia cells in the absence of P-glycoprotein overexpression. Cancer Res. 49: 4542-4549, 1989. PubMed: 2568172 |
